SEC Form 4 · accession 0001209191-16-151921
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Leber
Officer — Chief Communication Officer
Period of report
Nov 21, 2016
Accepted (ET)
Nov 23, 2016 · 2:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 10, 2016 | G | 173 | $0.00 | D | 17,799 | D | |
| Common Stock | Nov 21, 2016 | M | 3,600 | $17.41 | A | 21,399 | D | |
| Common StockF1,F2,F3,F4 | Nov 21, 2016 | S | 3,600 | $31.7252 | D | 17,799 | D | |
| Common StockF1,F2,F3,F4 | Nov 21, 2016 | S | 3,468 | $31.7346 | D | 14,331 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F5 | $17.41 | holding | — | — | — | — | Apr 26, 2017 | Common Stock | 0 | 0 | D |
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 8, 2016.
- F2Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F3Represents weighted average sale price. Actual sale prices ranged from $31.50 to $32.23.
- F4Includes an aggregate of 10,870 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F5The option became exercisable as to 25% of the shares on April 26, 2008, and became exercisable as to 1/48th of the shares each full month thereafter.